Chris Viehbacher, Biogen CEO (Suzanne Kreiter/The Boston Globe via Getty Images)
July 28, 2023 07:30 AM EDTUpdated 10:03 AM
Deals

Bio­gen makes its move, an­nounc­ing a $7.3B deal for Rea­ta

Kyle LaHucik

Senior Reporter

Bio­gen and its new CEO are fi­nal­ly wad­ing in­to 2023’s M&A wave with a $7.3 bil­lion deal for Rea­ta Phar­ma­ceu­ti­cals, which just se­cured FDA ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times